Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges

Madhav V. Dhodapkar; Joshua Richter

doi:10.1016/j.clim.2010.12.010

Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges

Madhav V. Dhodapkar, Joshua Richter

Research output: Contribution to journal › Review article › peer-review

49 Scopus citations

Abstract

Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor cells in myeloma express CD1d and are sensitive to lysis by CD1d restricted natural killer T (NKT) cells. Here we discuss recent studies to harness the properties of these cells in the context of human myeloma. In spite of large body of preclinical data, attempts to fully harness the properties of these cells in the clinic are in early stages. Early phase clinical studies document the capacity of human monocyte-derived dendritic cells to expand NKT cells in vivo in myeloma patients. These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well.

Original language	English
Pages (from-to)	160-166
Number of pages	7
Journal	Clinical Immunology
Volume	140
Issue number	2
DOIs	https://doi.org/10.1016/j.clim.2010.12.010
State	Published - Aug 2011
Externally published	Yes

Keywords

Immunotherapy
Myeloma
NKT cells

Access to Document

10.1016/j.clim.2010.12.010

Cite this

@article{4196c4550b4f4b1585c32dde6b947b78,

title = "Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges",

abstract = "Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor cells in myeloma express CD1d and are sensitive to lysis by CD1d restricted natural killer T (NKT) cells. Here we discuss recent studies to harness the properties of these cells in the context of human myeloma. In spite of large body of preclinical data, attempts to fully harness the properties of these cells in the clinic are in early stages. Early phase clinical studies document the capacity of human monocyte-derived dendritic cells to expand NKT cells in vivo in myeloma patients. These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well.",

keywords = "Immunotherapy, Myeloma, NKT cells",

author = "Dhodapkar, {Madhav V.} and Joshua Richter",

note = "Funding Information: MVD is supported in part by funds from NIH and Leukemia and Lymphoma Society.",

year = "2011",

month = aug,

doi = "10.1016/j.clim.2010.12.010",

language = "English",

volume = "140",

pages = "160--166",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Harnessing natural killer T (NKT) cells in human myeloma

T2 - Progress and challenges

AU - Dhodapkar, Madhav V.

AU - Richter, Joshua

N1 - Funding Information: MVD is supported in part by funds from NIH and Leukemia and Lymphoma Society.

PY - 2011/8

Y1 - 2011/8

N2 - Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor cells in myeloma express CD1d and are sensitive to lysis by CD1d restricted natural killer T (NKT) cells. Here we discuss recent studies to harness the properties of these cells in the context of human myeloma. In spite of large body of preclinical data, attempts to fully harness the properties of these cells in the clinic are in early stages. Early phase clinical studies document the capacity of human monocyte-derived dendritic cells to expand NKT cells in vivo in myeloma patients. These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well.

AB - Multiple myeloma is a hematologic malignancy characterized by growth of malignant plasma cells in the bone marrow. Tumor cells in myeloma express CD1d and are sensitive to lysis by CD1d restricted natural killer T (NKT) cells. Here we discuss recent studies to harness the properties of these cells in the context of human myeloma. In spite of large body of preclinical data, attempts to fully harness the properties of these cells in the clinic are in early stages. Early phase clinical studies document the capacity of human monocyte-derived dendritic cells to expand NKT cells in vivo in myeloma patients. These results have set the stage for ongoing studies combining NKT activation with immune-modulatory drugs. Lessons learnt from these studies may inform the optimal application of human NKT based therapies in other settings as well.

KW - Immunotherapy

KW - Myeloma

KW - NKT cells

UR - http://www.scopus.com/inward/record.url?scp=79960454502&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2010.12.010

DO - 10.1016/j.clim.2010.12.010

M3 - Review article

C2 - 21233022

AN - SCOPUS:79960454502

SN - 1521-6616

VL - 140

SP - 160

EP - 166

JO - Clinical Immunology

JF - Clinical Immunology

IS - 2

ER -

Harnessing natural killer T (NKT) cells in human myeloma: Progress and challenges

Abstract

Keywords

Access to Document

Fingerprint

Cite this